AVADEL PHARMACEUTICALS PLC — Director's Dealing 2018

Jun 29, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVADEL PHARMACEUTICALS PLC (FLML)
CIK: 0001012477
Period of Report: 2018-06-26

Reporting Person: KANAN MICHAEL F (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-06-26	ADSs	P	1967	$5.70	Acquired	37967	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$16.21	2025-10-28	ADSs (100000)	100000	Direct
Stock Option (right to buy)	$10.4	2026-12-14	ADSs (100000)	100000	Direct
Stock Option (right to buy)	$8.95	2027-12-12	ADSs (80000)	80000	Direct

Footnotes

F1: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

F2: Includes (a) 18,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date; and (b) 18,000 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, under which 12,000 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 6,000 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant).

F3: Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 10/28/2015 grant date.

F4: Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.

F5: Options become exercisable as to 20,000 ADSs on each of the first four anniversaries after the 12/12/2017 grant date.